menu
    • menu
    [{"orgOrder":0,"company":"CBC Group","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"CBC Group","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"CBC Group \/ CBC Group"},{"orgOrder":0,"company":"CBC Group","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CBC Group","amount2":0.32000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.32000000000000001,"dosageForm":"Tablet","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"CBC Group \/ CBC Group"},{"orgOrder":0,"company":"CBC Group","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Divestment","leadProduct":"Levetiracetam","moa":"Voltage-gated N-type calcium channel alpha-1B subunit | Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"CBC Group","amount2":0.68000000000000005,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.68000000000000005,"dosageForm":"Syrup","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"CBC Group \/ CBC Group"},{"orgOrder":0,"company":"CBC Group","sponsor":"Adcentrx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"CBC Group","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"2","companyTruncated":"CBC Group \/ CBC Group"}]

    Find Clinical Drug Pipeline Developments & Deals by CBC Group

    Menu

    CBC Group

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CBC Group

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CBC Group

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levetiracetam

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : UCB Pharma S.A

                            Deal Size : $680.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Belgium's UCB to sell China neurology, allergy business for $680 mln

                            Details : UCB is divesting its mature neurology and allergy business in China, which includes Keppra (levetiracetam), a medication used for the treatment of seizures, to CBC Group.

                            Product Name : Keppra

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 26, 2024

                            Lead Product(s) : Levetiracetam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : UCB Pharma S.A

                            Deal Size : $680.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CBC Group

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CBC Group

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oliceridine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Trevena

                            Deal Size : $40.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

                            Details : The funding was triggered by the first commercial sale of OLINVYK (oliceridine), contains oliceridine, an opioid, which is a Schedule II controlled substance, indicated in adults for the management of acute pain severe, in China by Jiangsu Nhwa.

                            Product Name : Olinvyk

                            Product Type : Miscellaneous

                            Upfront Cash : $15.0 million

                            September 06, 2023

                            Lead Product(s) : Oliceridine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Trevena

                            Deal Size : $40.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CBC Group

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CBC Group

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Hasten Biopharmaceutic

                            Deal Size : $315.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma

                            Details : The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, ...

                            Product Name : Edarbi

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 20, 2023

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Hasten Biopharmaceutic

                            Deal Size : $315.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CBC Group

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CBC Group

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Adcentrx Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Adcentrx Complete $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Resea...

                            Details : Series A financing is raised to power the development of next generation ADC for improving patient treatment options.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 28, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Adcentrx Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth